PBGENE-HBV is designed to potentially cure chronic hepatitis B by eliminating the root cause of the virus. The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an ...

Fewer than 1 in 3 children with hepatitis C (HCV) see a clinician for care, and fewer than 1 in 8 receive treatment.

Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the acceptance of five abstracts, including a late-breaking study, for ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs ...

Shares of Precision BioSciences DTIL rallied 23.8% on Tuesday after the company’s announcement that the FDA has granted Fast ...

Background and Aims: Long-term lamivudine therapy is required for patients with chronic hepatitis B, because hepatitis reappears frequently after it has withdrawn. However, hepatitis B virus (HBV ...

Merck & Co has axed two hepatitis drugs in its pipeline, a further indication that competitors think the market has peaked. The company already markets Zepatier (elbasvir+grazoprevir), which got ...

Federal parties have pitched different approaches to dealing with the toxic drug crisis in B.C. — particularly when it comes to overdose prevention and supervised consumption sites.

HBV=hepatitis B virus. HBVDR=HBV drug resistance. i-GAP=integrated Global Action Plan. RAM=resistance-associated mutation(s). ∗Newly proposed definitions, based on those used in the HIV drug ...

This may include an evaluation of your drug and alcohol use, sexual history (a risk factor for hepatitis B), injecting drug use (a risk factor for hepatitis B and C), and blood transfusions before ...

To make matters worse, it found that the addition of drug possession decriminalization ... concerns about whether the federal Liberals and B.C. NDP acted recklessly by forwarding these untested ...